First-in-human (FIH) trial evaluating immune activation and safety of PIN-2 administered intravenously to patients with advanced solid tumors.

被引：0
作者：
Bier, Colin
Millward, Michael
Kotasek, Dusan
Gorelick, Kenneth J.
Goldberg, Joshua Brian
机构：
[1] PIN Pharma Inc, New York, NY USA
[2] Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Adelaide Canc Ctr, Kurralta Pk, Adelaide, SA, Australia
[4] Univ Adelaide, Kurralta Pk, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2600
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors.
    Boni, Valentina
    Garralda, Elena
    Colombo, Ilaria
    Homicsko, Krisztian
    Brana, Irene
    Gruber, Dorothea
    Fluckiger-Mangual, Stefanie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
    McKean, Meredith
    Hutson, Thomas E.
    Piha-Paul, Sarina A.
    Micaily, Ida
    Liao, Mingxiang
    Humphreys, Robin
    Brock, Graham
    Sahr, Natasha
    Amber, Vian
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
    Hong, David S.
    Kurzrock, Razelle
    Supko, Jeffrey G.
    He, Xiaoying
    Naing, Aung
    Wheler, Jennifer
    Lawrence, Donald
    Eder, Joseph Paul
    Meyer, Colin J.
    Ferguson, Deborah A.
    Mier, James
    Konopleva, Marina
    Konoplev, Sergej
    Andreeff, Michael
    Kufe, Donald
    Lazarus, Hillard
    Shapiro, Geoffrey I.
    Dezube, Bruce J.
    CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3396 - 3406
  • [24] A first-in-human phase I study of ER-α36 modifier icaritin in patients with advanced solid tumors.
    Fan, Ying
    Xu, Binghe
    Ding, Xiaoyan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Luo, Yang
    Li, Qing
    Zhang, Pin
    Cai, Ruigang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
    Dolly, S. O.
    Albanell, J.
    Kraeber-Bodere, F.
    Banerji, U.
    Bahleda, R.
    Garcia, M. Martinez
    Xu, Z. X.
    Guarin, E.
    Tessier, J.
    Shochat, E.
    Deutsch, J.
    Blotner, S.
    Meresse, V.
    Soria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
    Herbst, Roy S.
    Kurzrock, Razelle
    Hong, David S.
    Valdivieso, Manuel
    Hsu, Cheng-Pang
    Goyal, Lovely
    Juan, Gloria
    Hwang, Yuying C.
    Wong, Susan
    Hill, John S.
    Friberg, Greg
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5883 - 5891
  • [27] A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    Carneiro, Ana
    Nielsen, Dorte
    Rohrberg, Kristoffer Staal
    Kvarnhammar, Anne Mansson
    Dahlman, Anna
    Bageman, Erika
    Wennersten, Camilla
    Russell, Charlotte Astrid
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
    Creelan, Ben C.
    Gabrilovich, Dmitry I.
    Gray, Jhanelle E.
    Williams, Charles C.
    Tanvetyanon, Tawee
    Haura, Eric B.
    Weber, Jeffrey S.
    Gibney, Geoffrey T.
    Markowitz, Joseph
    Proksch, Joel W.
    Reisman, Scott A.
    McKee, Mark D.
    Chin, Melanie P.
    Meyer, Colin J.
    Antonia, Scott J.
    ONCOTARGETS AND THERAPY, 2017, 10 : 4239 - 4250
  • [29] First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors.
    Shapiro, Geoffrey
    LoRusso, Patricia
    Vaishampayan, Ulka N.
    Kittaneh, Muaiad
    Hilton, John Frederick
    Cleary, James M.
    Velastegui, Karen
    Xuan, Dawei
    Hua, Steven
    Shazer, Ronald L.
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.
    Shimizu, Toshio
    Fujiwara, Yutaka
    Yonemori, Kan
    Koyama, Takafumi
    Shimomura, Akihiko
    Tamura, Kenji
    Iwasa, Satoru
    Sato, Jun
    Kitano, Shigehisa
    Ikezawa, Hiroki
    Nomoto, Maiko
    Nakajima, Ryo
    Miura, Takuma
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345